Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Hinge Health enters the first week of October with a shift in the short-selling trend that reverses the retreat documented just days ago, while options traders remain positioned firmly on the bullish side and the Street keeps lifting its targets ahead of a November 2 earnings date.
The positioning story has turned in one direction since the previous note. Short interest has crept back up to 14.9% of the free float, a 3.1% increase over the past week and 5% higher than a month ago. That is a partial reversal of the unwind that ran through mid-September, when shorts had pulled back from a peak above 6 million shares. The borrow market offers no friction for this rebuilding: cost to borrow is running at just 0.39%, and availability is extremely loose at roughly 1,118% of short interest, meaning there are far more shares available to lend than are currently borrowed. Shorts face no squeeze pressure from the lending market. The ORTEX short score has drifted marginally higher to 48.2, moving in the same direction as the incremental short rebuilding, though it remains in neutral territory.
Options traders have not followed the shorts in turning more cautious. The put/call ratio is 0.35, well below its 20-day average of 0.51 and close to the 52-week floor of 0.27. That compares with readings above 0.86 in early September, before the August earnings print. The z-score of negative 0.66 confirms the current stance is lighter on puts than usual, though the divergence from the short-interest rebuild is the interesting tension here. Call positioning dominates even as shorts add. Whether that reflects a bullish bet on the November print or simply the mechanical effect of a stock that has risen 3.3% on the week and 6.5% over the past month is not clear from the data alone.
The Street is broadly onside with the stock. The consensus sits at a mean price target of $110.56 against a current price of $98.35, implying roughly 12% potential upside. Needham raised its target to $115 at the end of September, maintaining a Buy, while Baird lifted its Neutral-rated target to $90. That combination captures the bull-bear divide in one sentence: the bullish camp sees a highly scalable AI-enabled musculoskeletal platform with win rates above 80%, 97% client retention, and a growing footprint across fully insured health plans, with above-consensus 2027 growth possible if Surgery and migraine products expand the market. Bears point to August monthly active users falling 8% year-on-year to 527,400, the first year-on-year decline in that series, and question whether durable engagement can support the economics at scale. EV/EBITDA is running at 25.1x and the price-to-earnings multiple at 33.9x, both drifting slightly lower over the past month, which represents mild multiple compression even as the price has risen. The analyst recommendation differential ranks in the 98th percentile of the ORTEX universe, suggesting the Street's conviction is unusually high relative to most names.
The ownership picture adds another layer. The 90-day net insider position is minus 772,761 shares worth approximately $69.7 million, a material outflow. The bulk came from President James Pursley and director Gabriel Mecklenburg, both selling in mid-to-late September under pre-arranged 10b5-1 plans, which limits the bearish read on those transactions. The largest holder, co-founder Daniel Perez, held 10 million shares as of his most recent filing. BlackRock added 2.66 million shares in the period to September 30, the most notable institutional move in the data. On the 13D/G register, no activist stake is present, and several original venture backers including Coatue and Vanguard have disclosed positions that have fallen or reached zero since their initial filings, consistent with a stock that has more than doubled this year and where early investors are distributing. Stakes in that register are as-last-disclosed around the 5% threshold; holders dropping below 5% may not file again.
Wikipedia retail attention for Hinge Health ranked at a z-score of 3.0 against its own 90-day history as of late September, a notable spike in public interest for a company that flew below most retail radar screens before this year's run.
With earnings on November 2, the next 26 days will determine whether the short rebuilding is positioned correctly against what the August MAU data implied or whether the Street's target-raising and the call-heavy options book prove to be the better read.
See the live data behind this article on ORTEX.
Open HNGE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
